Saturday, March 18, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biodetection

Tangen BioSciences’ Anthrax Diagnostic Awarded 3.2M BARDA Contract

by Global Biodefense Staff
November 27, 2017
Bacillus anthracis rapid diagnostic development

Bacillus anthracis rapid diagnostic developmentThe Biomedical Advanced Research and Development Authority (BARDA) has awarded funding to Tangen BioSciences for advanced development of the company’s rapid anthrax diagnostic.

The $3,199,221 base period award was announced by BARDA on Nov 20.

Rapid diagnosis of anthrax infections allows for more effective treatment, protection of response personnel, and deployment of resources adequate for the scope of infected victims. If approved, the TangenDx™ System could be used to determine whether a symptomatic patient had been infected with anthrax-causing Bacillus anthracis bacteria in as little as 15 minutes. BARDA’s portfolio includes supporting three anthrax antitoxin drugs approved by the FDA.

Preliminary data indicate that the TangenDx™ System could be as sensitive as current blood cultures with results hours quicker. The test can be based on a wide range of specimen types, including blood, sputum, and other methods of specimen sampling.

BARDA also supports advanced development of vaccines to prevent illness after exposure to anthrax and improvements to the only anthrax vaccine licensed for use post-exposure so that fewer doses are needed to protect human health.

Editor also recommends:

  • Rapid Detection of Multiple Drug-resistant TB from Sputum
  • Elusys Delivers Anthrax Countermeasure Order, Gains Funding for Lyophilization Effort
  • Anthrax: DoD Develops Biological Select Agents and Toxins Surrogate Solution
  • BARDA Awards 2.5M Contract to Advance Anthrax Diagnostic
  • Sandia Labs Recognized for Ruggedized Anthrax Detector
  • DHS Funds Further Development of Anthrax Diagnostic
Tags: AnthraxASPRAwardsBARDABioterrorismHHSPOC DiagnosticsSelect Agents

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
DoD Awards ENA Respiratory $4.38M for Broad-Spectrum Antiviral Development
Industry News

DoD Awards ENA Respiratory $4.38M for Broad-Spectrum Antiviral Development

January 10, 2023
New Material Helps Train First Responders on Biothreats
Biodetection

New Material Helps Train First Responders on Biothreats

January 4, 2023
Load More

Latest News

Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC